vs

Side-by-side financial comparison of Exodus Movement, Inc. (EXOD) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is the larger business by last-quarter revenue ($44.6M vs $29.4M, roughly 1.5× Exodus Movement, Inc.). PACIFIC BIOSCIENCES OF CALIFORNIA, INC. runs the higher net margin — -90.4% vs -181.0%, a 90.6% gap on every dollar of revenue. On growth, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. posted the faster year-over-year revenue change (13.8% vs -34.4%). PACIFIC BIOSCIENCES OF CALIFORNIA, INC. produced more free cash flow last quarter ($-19.9M vs $-25.8M). Over the past eight quarters, PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s revenue compounded faster (7.3% CAGR vs 0.6%).

Exodus is a cryptocurrency wallet available on desktop and mobile platforms. It was founded in 2015 by JP Richardson and Daniel Castagnoli. Exodus wallet supports digital assets including Bitcoin, Ethereum, and Solana. It is available on Windows, macOS, Linux, iOS, Android, and as a browser extension.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

EXOD vs PACB — Head-to-Head

Bigger by revenue
PACB
PACB
1.5× larger
PACB
$44.6M
$29.4M
EXOD
Growing faster (revenue YoY)
PACB
PACB
+48.2% gap
PACB
13.8%
-34.4%
EXOD
Higher net margin
PACB
PACB
90.6% more per $
PACB
-90.4%
-181.0%
EXOD
More free cash flow
PACB
PACB
$5.9M more FCF
PACB
$-19.9M
$-25.8M
EXOD
Faster 2-yr revenue CAGR
PACB
PACB
Annualised
PACB
7.3%
0.6%
EXOD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EXOD
EXOD
PACB
PACB
Revenue
$29.4M
$44.6M
Net Profit
$-53.2M
$-40.4M
Gross Margin
37.1%
Operating Margin
-226.9%
-92.3%
Net Margin
-181.0%
-90.4%
Revenue YoY
-34.4%
13.8%
Net Profit YoY
-179.5%
-1802.7%
EPS (diluted)
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXOD
EXOD
PACB
PACB
Q4 25
$29.4M
$44.6M
Q3 25
$30.3M
$38.4M
Q2 25
$25.8M
$39.8M
Q1 25
$36.0M
$37.2M
Q4 24
$44.8M
$39.2M
Q3 24
$20.1M
$40.0M
Q2 24
$22.3M
$36.0M
Q1 24
$29.1M
$38.8M
Net Profit
EXOD
EXOD
PACB
PACB
Q4 25
$-53.2M
$-40.4M
Q3 25
$17.0M
$-38.0M
Q2 25
$37.7M
$-41.9M
Q1 25
$-12.9M
$-426.1M
Q4 24
$66.9M
$2.4M
Q3 24
$843.0K
$-60.7M
Q2 24
$-9.6M
$-173.3M
Q1 24
$54.8M
$-78.2M
Gross Margin
EXOD
EXOD
PACB
PACB
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
43.7%
25.0%
Q2 24
51.7%
16.5%
Q1 24
63.2%
29.1%
Operating Margin
EXOD
EXOD
PACB
PACB
Q4 25
-226.9%
-92.3%
Q3 25
66.9%
-101.1%
Q2 25
-112.8%
Q1 25
-60.4%
-1154.5%
Q4 24
-390.1%
Q3 24
-0.3%
-160.3%
Q2 24
-66.1%
-488.3%
Q1 24
-209.6%
Net Margin
EXOD
EXOD
PACB
PACB
Q4 25
-181.0%
-90.4%
Q3 25
56.2%
-98.9%
Q2 25
145.8%
-105.4%
Q1 25
-35.8%
-1146.8%
Q4 24
149.4%
6.0%
Q3 24
4.2%
-151.9%
Q2 24
-43.1%
-481.3%
Q1 24
188.5%
-201.4%
EPS (diluted)
EXOD
EXOD
PACB
PACB
Q4 25
$-0.11
Q3 25
$-0.13
Q2 25
$-0.14
Q1 25
$-1.44
Q4 24
$-0.44
Q3 24
$-0.22
Q2 24
$-0.64
Q1 24
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXOD
EXOD
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$4.9M
$279.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$247.4M
$5.3M
Total Assets
$266.8M
$784.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXOD
EXOD
PACB
PACB
Q4 25
$4.9M
$279.5M
Q3 25
$50.5M
$298.7M
Q2 25
$52.9M
$314.7M
Q1 25
$59.8M
$343.1M
Q4 24
$37.9M
$389.9M
Q3 24
$26.5M
$471.1M
Q2 24
$27.8M
$509.8M
Q1 24
$21.0M
$561.9M
Stockholders' Equity
EXOD
EXOD
PACB
PACB
Q4 25
$247.4M
$5.3M
Q3 25
$296.7M
$36.1M
Q2 25
$277.1M
$61.5M
Q1 25
$241.5M
$91.6M
Q4 24
$257.5M
$506.6M
Q3 24
$191.2M
$453.1M
Q2 24
$190.8M
$492.7M
Q1 24
$199.1M
$649.0M
Total Assets
EXOD
EXOD
PACB
PACB
Q4 25
$266.8M
$784.1M
Q3 25
$338.5M
$803.2M
Q2 25
$313.7M
$825.5M
Q1 25
$263.2M
$860.8M
Q4 24
$288.0M
$1.3B
Q3 24
$211.6M
$1.5B
Q2 24
$211.6M
$1.5B
Q1 24
$225.4M
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXOD
EXOD
PACB
PACB
Operating Cash FlowLast quarter
$-25.6M
$-19.1M
Free Cash FlowOCF − Capex
$-25.8M
$-19.9M
FCF MarginFCF / Revenue
-87.9%
-44.6%
Capex IntensityCapex / Revenue
0.9%
1.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-42.3M
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXOD
EXOD
PACB
PACB
Q4 25
$-25.6M
$-19.1M
Q3 25
$-4.8M
$-18.7M
Q2 25
$-5.3M
$-29.4M
Q1 25
$-6.2M
$-44.1M
Q4 24
$-12.0M
$-30.6M
Q3 24
$-4.9M
$-45.5M
Q2 24
$-2.4M
$-54.3M
Q1 24
$450.0K
$-75.7M
Free Cash Flow
EXOD
EXOD
PACB
PACB
Q4 25
$-25.8M
$-19.9M
Q3 25
$-4.8M
$-18.8M
Q2 25
$-5.4M
$-29.9M
Q1 25
$-6.2M
$-45.4M
Q4 24
$-12.3M
$-32.3M
Q3 24
$-4.9M
$-46.3M
Q2 24
$-2.4M
$-55.7M
Q1 24
$300.0K
$-79.6M
FCF Margin
EXOD
EXOD
PACB
PACB
Q4 25
-87.9%
-44.6%
Q3 25
-16.0%
-48.9%
Q2 25
-20.7%
-75.3%
Q1 25
-17.3%
-122.3%
Q4 24
-27.5%
-82.3%
Q3 24
-24.5%
-115.7%
Q2 24
-10.8%
-154.8%
Q1 24
1.0%
-205.0%
Capex Intensity
EXOD
EXOD
PACB
PACB
Q4 25
0.9%
1.9%
Q3 25
0.1%
0.2%
Q2 25
0.4%
1.4%
Q1 25
0.1%
3.7%
Q4 24
0.6%
4.1%
Q3 24
0.2%
2.0%
Q2 24
0.2%
4.1%
Q1 24
0.5%
10.0%
Cash Conversion
EXOD
EXOD
PACB
PACB
Q4 25
Q3 25
-0.28×
Q2 25
-0.14×
Q1 25
Q4 24
-0.18×
-12.93×
Q3 24
-5.80×
Q2 24
Q1 24
0.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXOD
EXOD

Exchange Aggregation$26.6M90%
Other$2.8M10%

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons